Acumen Pharmaceuticals, Inc. (ABOS) AI Stock Analysis
ABOS AI stock analysis summary
AI ResearchAcumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company focused on developing targeted treatments for Alzheimer's disease. The company generated $329,000 in trailing twelve-month revenue and reported an EPS of -$1.64 for the period ending June 30, 2026. Acumen holds $110.2M in cash and short-term investments, providing $78.6M in net cash to advance its clinical pipeline.
- Market cap
- $122.2M
- Revenue (TTM)
- $329,000
- P/E
- —
- 1Y return
- -20.7% S&P 500 16.8%
- Avg. target
- $7.60 349.7% vs last close
Bull case
- Acumen maintains a solid balance sheet with $110.2M in cash and short-term investments and net cash of $78.6M as of June 30, 2026.
- All 6 covering analysts assign the stock a Strong Buy rating, with an average price target of $7.60 indicating 349.7% upside to the last close.
- The company demonstrated execution relative to expectations by beating quarterly EPS estimates in 3 of the last 4 quarters.
Bear case
- Acumen generated minimal commercial revenue of $329,000 over the trailing twelve months and posted a net loss of -$100.6M in FY2021.
- The stock trades at a price-to-sales ratio of 538.8x, far higher than the US-listed Healthcare peer median of 4.1x.
- Long-term share performance has lagged significantly, dropping 87.5% over the past 5 years while the S&P 500 advanced 83.0%.
What Acumen Pharmaceuticals does
Acumen Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies aimed at combating Alzheimer's disease. Founded in 1996 and headquartered in Charlottesville, Virginia, the company focuses on advancing its lead drug candidate, ACU193. ACU193 is a humanized monoclonal antibody currently undergoing Phase I clinical trials, specifically designed to target soluble amyloid-beta oligomers, which are believed to play a crucial role in the pathogenesis of Alzheimer's. Beyond ACU193, Acumen is actively engaged in expanding its pipeline of potential treatments for Alzheimer's disease through internal research and strategic partnerships.
Growth and profitability
Acumen generated annual revenue of $1.7M in FY2019, which fell 15.4% to $1.4M in FY2020 and remained flat at $1.4M in FY2021, representing a two-year revenue CAGR of -8.0%. Operating margin moved from -459.9% in FY2019 to -551.0% in FY2020 and -1363.8% in FY2021 as R&D expense increased from $8.6M in FY2019 to $12.3M in FY2021. Net income widened from -$7.9M in FY2019 to -$100.6M in FY2021, resulting in FY2021 EPS of -$9.37. For the trailing twelve months ending June 30, 2026, revenue was $329,000, operating margin was 0.0%, and EPS stood at -$1.64.
Balance sheet and cash flow
As of June 30, 2026, Acumen held $110.2M in cash and short-term investments alongside total debt of $31.6M, resulting in net cash of $78.6M. The company reported total assets of $116.0M, shareholders' equity of $57.3M, and a current ratio of 2.47, with a debt-to-equity ratio of 0.55. Operating cash flow in FY2021 was -$18.0M, matching free cash flow of -$18.0M. During FY2025, capital expenditures were $88,000 and share buybacks totaled $73,000, while the five-year share count increased by 88.8%.
Valuation and performance
Acumen trades at an enterprise value of $88.1M and a market capitalization of $122.2M, with a price-to-sales multiple of 538.8x compared to the median of 4.1x for its US-listed Healthcare peers. Its EV-to-revenue multiple stands at 24.5x, and its price-to-book ratio is 2.9x. Over the past year, the stock fell 20.7%, while the S&P 500 (SPY) returned 16.8%. Over a 5-year period, the stock dropped 87.5% compared to an 83.0% gain for the S&P 500. Shares closed at $1.69 on October 16, 2026, trading 32.4% below their 200-day moving average.
What analysts expect
Wall Street coverage consists of 6 Strong Buy ratings with zero Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $7.60, representing a 349.7% premium over the October 16, 2026 closing price of $1.69. For FY2026, analysts estimate an EPS of -$1.62 and revenue of $0, representing 19.0% EPS growth. For FY2027, 3 analysts project an EPS of -$1.43 on revenue of $0. Acumen exceeded EPS estimates in 3 of the last 4 quarters, with its next earnings report scheduled for November 11, 2026.
Key risks and what to watch
- Ongoing clinical development creates continuous cash burn, evidenced by free cash flow of -$18.0M in FY2021.
- Shareholders face ongoing dilution risk, as the company's share count increased by 88.8% over the trailing 5-year period.
- Analyst estimates project $0 in revenue for both FY2026 and FY2027, making financial sustainability dependent on capital raises or partnership funding.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ABOS AI stock analysis
This page is an AI-written research summary of Acumen Pharmaceuticals, Inc. (ABOS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ABOS income statement, ABOS balance sheet, ABOS key metrics, ABOS analyst forecast, ABOS chart. See the ABOS stock overview for the latest quote and news.
ABOS AI stock analysis FAQ
What does Acumen Pharmaceuticals do?
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for Alzheimer's disease. Its lead drug candidate, ACU193, is a humanized monoclonal antibody in Phase I clinical trials targeting soluble amyloid-beta oligomers.
Does Acumen Pharmaceuticals pay a dividend?
Acumen Pharmaceuticals does not pay a dividend. The company channels its financial resources into clinical research and development, including $12.3M spent on R&D in FY2021.
What is Acumen's current cash and debt position?
As of June 30, 2026, Acumen had $110.2M in cash and short-term investments and $31.6M in total debt, resulting in net cash of $78.6M. Its current ratio stood at 2.47.
What are analysts' price targets and ratings for ABOS?
Covering analysts hold 6 Strong Buy ratings with no Hold or Sell recommendations. The average price target is $7.60, which is 349.7% above the last close of $1.69.